

detection for the identification and quantification of this analyte. The limit of quantitation (LOQ) for bifentazate in corn matrices and processed commodities was 0.01 ppm. The limit of detection (LOD) for the method is set at 0.005 ppm. The method has also been validated by liquid chromatography/mass spectrometry/mass spectroscopy (LC/MS/MS), and used for the confirmation of residues for corn raw agricultural commodities (RAC) and processed commodities. The analytical method for bifentazate and its major metabolite D3598, in animal tissues was designed using the same principles invoked in the plant method, with minor modifications. However, in animal tissue samples, a separate aliquot of the extract was used to determine residues of A1530, and its sulfate (combined) in milk and meat samples (as these metabolites appeared to be significant in the goat metabolism studies). The extract was subjected to acid hydrolysis to convert the sulfate conjugate to A1530, before it was quantified by LC/MS/MS. Another metabolite, D9569, was also monitored in milk by LC/MS/MS. Contact: Amer Al-Mudallal, (703) 605-0566; al-mudallal.amer@epa.gov.

2. *PP 8F7395*. (EPA-HQ-OPP-2008-0646). Valent U.S.A. Corporation, P.O. Box 8025, Walnut Creek, CA 94596 (as Agent for Sumitomo Chemical Company, Ltd.), proposes to establish a tolerance for residues of the insecticide clothianidin, (*E*)-1-(2-chloro-1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine, in or on almond, hull at 1.5 ppm; cotton, seed at 0.25 ppm; cotton, gin trash at 4.5 ppm; cotton, meal at 0.25 ppm; cotton, hull at 0.25 ppm; cotton, refined oil at 0.01 ppm; soybean, seed at 0.03 ppm; soybean, hull at 0.35 ppm; soybean, meal at 0.07 ppm; soybean, oil at 0.01 ppm; tomato, paste at 0.08 ppm; tomato, puree at 0.07 ppm; nut, tree, group 14 at 0.01 ppm; vegetable, cucurbit, group 9 at 0.05 ppm; and vegetable, fruiting, group 8 at 0.25 ppm; and clothianidin, (*E*)-1-(2-chloro-1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine and its metabolite, *N*-(2-chlorothiazol-5-ylmethyl)-*N*-methylguanidine (TMG), in or on vegetable, leafy, brassica, group 5 at 3.0 ppm; and vegetable, leafy, except brassica, group 4 at 3.5 ppm. Adequate enforcement methodology LC/MS/MS analysis is available to enforce the tolerance expression. Contact: Kable Davis, (703) 306-0415; davis.kable@epa.gov.

New Exemption from an Inert Tolerance

PP 8E7402. (EPA-HQ-OPP-2008-0652). Falcon Lab, LLC, 1103 Norbee

Drive, Wilmington, DE 19803, proposes to establish an exemption from the requirement of a tolerance in 40 CFR 180.910 and 40 CFR 180.950 for residues of ammonium salts of higher fatty acids, [C₈-C₁₈ saturated and C₈-C₁₂ unsaturated, (CAS No. 84776-33-0)], when used as a pesticide inert ingredient in pesticide formulations in or on all food commodities. Because this petition is a request for an exemption from the requirement of a tolerance, no analytical method is required. Contact: Karen Samek, (703) 347-8825; samek.karen@epa.gov.

List of Subjects

Environmental protection, Agricultural commodities, Feed additives, Food additives, Pesticides and pests, Reporting and recordkeeping requirements.

Dated: August 27, 2008.

Donald R. Stubbs,

Acting Director, Registration Division, Office of Pesticide Programs.

[FR Doc. E8-20519 Filed 9-5-08; 8:45 am]

BILLING CODE 6560-50-S

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisition of Shares of Bank or Bank Holding Companies

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the office of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than September 22, 2008.

A. Federal Reserve Bank of Chicago (Burl Thornton, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414:

1. *Harrison I. Steans*, Bannockburn, Illinois, and Jennifer W. Steans, Evanston, Illinois, Financial Investments Corporation, PCB, LP, General Partners; Heather A. Steans; Robin M. Steans, all of Chicago, Illinois; Harrison I. Steans Self-Declaration of Revocable Trust – Harrison I. Steans, Trustee, both of Bannockburn, Illinois;

Jennifer W. Steans 1999 Descendants Trust – James P. Kastenholz, Trustee, both of Evanston, Illinois; Heather A. Steans 1999 Descendants Trust – Leo A. Smith, Trustee; Robin M. Steans 1999 Descendants Trust – Leonard A. Gail, Trustee, both of Chicago, Illinois; Jennifer W. Steans 2000 Trust – Jennifer W. Steans, Trustee, both of Evanston, Illinois; Heather A. Steans 2001 Trust – Heather A. Steans, Trustee; Robin M. Steans Revocable Trust – Robin M. Steans, Trustee, both of Chicago, Illinois; James P. Kastenholz 2000 Trust – James P. Kastenholz, Trustee, both of Evanston, Illinois; Leonard A. Gail Revocable Trust – Leonard A. Gail, Trustee, both of Chicago, Illinois; Hunter Family Foundation – Thomas B. Hunter, III, and Maxine M. Hunter, Trustees; Maxine M. Hunter Charitable Lead Annuity Trust – Thomas B. Hunter, IV, all of Lake Forest, Illinois, and Willard M. Hunter, Trustees, Lake Bluff, Illinois; Thomas B. Hunter, III Self Declaration of Revocable Trust – Thomas B. Hunter, III, Trustee; Morrison Family Foundation – Harold M. Morrison; Adeline S. Morrison, Trustees; Harold M. Morrison Trust – Harold M. Morrison, Trustee, all of Lake Forest, Illinois; and USAmeriBancorp, Largo, Florida, to acquire voting shares of Taylor Capital Group, Rosemont, Illinois, and thereby indirectly acquire control of Cole Taylor Bank, Chicago, Illinois.

Board of Governors of the Federal Reserve System, September 2, 2008.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. E8-20583 Filed 9-4-08; 8:45 am]

BILLING CODE 6210-01-S

FEDERAL RESERVE SYSTEM

Federal Open Market Committee; Domestic Policy Directive of August 5, 2008

In accordance with § 271.25 of its rules regarding availability of information (12 CFR part 271), there is set forth below the domestic policy directive issued by the Federal Open Market Committee at its meeting held on August 5, 2008.¹

The Federal Open Market Committee seeks monetary and financial conditions that will foster price stability and

¹ Copies of the Minutes of the Federal Open Market Committee meeting on August 5, 2008, which includes the domestic policy directive issued at the meeting, are available upon request to the Board of Governors of the Federal Reserve System, Washington, D.C. 20551. The minutes are published in the Federal Reserve Bulletin and in the Board's annual report.

promote sustainable growth in output. To further its long-run objectives, the Committee in the immediate future seeks conditions in reserve markets consistent with maintaining the federal funds rate at an average of around 2 percent.

By order of the Federal Open Market Committee, August 26, 2008.

Brian F. Madigan,

Secretary, Federal Open Market Committee.
[FR Doc. E8-20558 Filed 9-4-08; 8:45 am]

BILLING CODE 6210-01-S

FEDERAL TRADE COMMISSION

SES Performance Review Board

AGENCY: Federal Trade Commission

ACTION: Notice

SUMMARY: Notice is hereby given of the appointment of members to the Federal Trade Commission's Performance Review Board.

FOR FURTHER INFORMATION CONTACT:

Karen Leydon, Director of Human Resources, 600 Pennsylvania Avenue NW, Washington, DC 20580, (202) 326-2633.

SUPPLEMENTARY INFORMATION:

Publication of the Performance Review Board (PRB) membership is required by 5 U.S.C. 4314 (c)(4). The PRB reviews and evaluates the initial appraisal of a senior executive's performance by the supervisor, and makes recommendations regarding performance ratings, performance awards, and pay-for-performance pay adjustments to the FTC Chairman.

The following individuals have been designated to serve on the FTC's Performance Review Board:

Charles H. Schneider, Chairman

William Blumenthal

Pauline M. Ippolito

Lydia B. Parnes

David P. Wales

By direction of the Commission.

Donald S. Clark

Secretary

[FR Doc. E8-20571 Filed 9-4-08; 8:45 am]

BILLING CODE 6750-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[Document Identifier: CMS-10151 and CMS-10152]

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Centers for Medicare & Medicaid Services.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Centers for Medicare & Medicaid Services (CMS) is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

1. Type of Information Collection Request: Revision of a currently approved collection; **Title of Information Collection:** Data Collection for Medicare Beneficiaries Receiving Implantable Cardioverter-defibrillator for Primary Prevention of Sudden Cardiac Death; **Use:** The Centers for Medicare and Medicaid Services (CMS) provides coverage for implantable cardioverter-defibrillators (ICDs) for secondary prevention of sudden cardiac death based on extensive evidence showing that use of ICDs among patients with a certain set of physiologic conditions are effective. Accordingly, CMS considers coverage for ICDs reasonable and necessary under Section 1862 (a)(1)(A) of the Social Security Act. However, evidence for use of ICDs for primary prevention of sudden cardiac death is less compelling for certain patients.

To encourage responsible and appropriate use of ICDs, CMS issued a Decision Memo for Implantable Defibrillators on January 27, 2005, indicating that ICDs will be covered for primary prevention of sudden cardiac death if the beneficiary is enrolled in either an FDA-approved category B IDE clinical trial (42 CFR 405.201), a trial

under the CMS Clinical Trial Policy (NCD Manual § 310.1) or a qualifying prospective data collection system (either a practical clinical trial or prospective systematic data collection, which is sometimes referred to as a registry). **Form Number:** CMS-10151 (OMB# 0938-0967); **Frequency:** Reporting—Quarterly; **Affected Public:** Business or other for-profit and not-for-profit institutions; **Number of Respondents:** 1,217; **Total Annual Responses:** 50,000; **Total Annual Hours:** 12,500.

2. Type of Information Collection Request: Extension of a currently approved collection; **Title of Information Collection:** Data collection for Medicare Beneficiaries Receiving FDG Positron Emission Tomography (PET) for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and All Other Cancers **Use:** In the Decision Memo #CAG-00181N issued on January 27, 2005, CMS determined that the evidence is sufficient to conclude that for Medicare beneficiaries receiving FDG positron emission tomography (PET) for brain, cervical, ovarian, pancreatic, small cell lung, and testicular cancers is reasonable and necessary only when the provider is participating in and patients are enrolled in a systematic data collection project. CMS will consider prospective data collection systems to be qualified if they provide assurance that specific hypotheses are addressed and they collect appropriate data elements. The data collection should include baseline patient characteristics; indications for the PET scan; PET scan type and characteristics; FDG PET results; results of all other imaging studies; facility and provider characteristics; cancer type, grade, and stage; long-term patient outcomes; disease management changes; and anti-cancer treatment received. **Form Number:** CMS-10152 (OMB# 0938-0968); **Frequency:** Reporting—On occasion; **Affected Public:** Business or other for-profit and not-for-profit institutions; **Number of Respondents:** 2,000; **Total Annual Responses:** 50,000; **Total Annual Hours:** 4,167.

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access CMS' Web Site at <http://www.cms.hhs.gov/PaperworkReductionActof1995>, or E-mail your request, including your address, phone number, OMB number, and CMS document identifier, to Paperwork@cms.hhs.gov, or call the Reports Clearance Office on (410) 786-1326.

In commenting on the proposed information collections please reference